Stayble Therapeutics AB (publ) (FRA:4K4)
Germany · Delayed Price · Currency is EUR 0.0174
+0.0006 (3.57%)
At close: Nov 28, 2025
Stayble Therapeutics AB Company Description
Stayble Therapeutics AB (publ) develops injectable treatment for chronic pain triggered by disc degeneration.
The company develops STA363, an injection into the disc that targets chronic low back and leg pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
Stayble Therapeutics AB (publ)
| Country | Sweden |
| Founded | 2015 |
| Industry | Pharmaceutical Preparations |
| Employees | 2 |
| CEO | Andreas Gerward |
Contact Details
Address: Lennart Torstenssonsgatan 6 Gothenburg, 412 56 Sweden | |
| Website | staybletherapeutics.se |
Stock Details
| Ticker Symbol | 4K4 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andreas Gerward | Chief Executive Officer |
| Erik Kullgren | Chief Financial Officer |